Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: A Significant Cause of End-Stage Kidney Disease in Children
Article Sidebar
Main Article Content
Abstract
Introduction: Membranoproliferative glomerulonephritis (MPGN) is a significant cause of glomerulopathy and chronic kidney disease (CKD) or end-stage renal disease (ESRD) in children. The deposition of circulating immune complexes in the glomerulus and abnormal activation of the alternative complement pathway is believed to trigger the disease. However, there is limited knowledge regarding the optimal treatment and prognosis for children with immune complex-associated MPGN (IC-MPGN) and C3 glomerulopathy (C3G).
Case report: We report the case of a 14-year-old child admitted for rapidly progressive glomerulonephritis with anuria managed on haemodialysis. The kidney biopsy showed an appearance compatible with MPGN on light microscopy, with immunoglobulin and complement C3 deposits on direct immunofluorescence. The prognosis was poor, with rapid progression to ESRD despite treatment combining corticosteroid therapy and immunosuppressants.
Discussion and conclusion: Evaluating the effectiveness of different therapeutic approaches for MPGN in children is challenging due to the small sample sizes and the short duration of the published controlled studies. As a result, it is crucial to conduct more comprehensive trials that focus on both prognosis and treatment options.
Article Details
Copyright (c) 2025 Bouchoual M, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Clinical Nephrology is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Clinical Nephrology is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol. 2015;11:14–22. Available from: https://doi.org/10.1038/nrneph.2014.217
Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, et al. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/ immune complex-mediated membranoproliferative GN. J Am Soc Nephrol. 2018;29:283–294. Available from: https://doi.org/10.1681/asn.2017030258
Kovala M, Seppälä M, Räisänen-Sokolowski A, Meri S, Honkanen E, Kaartinen K. Diagnostic and prognostic comparison of immune-complex-mediated membranoproliferative glomerulonephritis and C3 glomerulopathy. Cells. 2023;12:712. Available from: https://doi.org/10.3390/cells12050712
Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016;71:131–142. Available from: https://doi.org/10.1016/j.molimm.2016.01.010
Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, et al. Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN. Front Immunol. 2018;9:2329. Available from: https://doi.org/10.3389/fimmu.2018.02329
Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant. 2012;27:4288–4294. Available from: https://doi.org/10.1093/ndt/gfs288
Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis– a new look at an old entity. N Engl J Med. 2012;366:1119–1131. Available from: https://doi.org/10.1056/nejmra1108178
Fakhouri F, Le Quintrec M, Frémeaux-Bacchi V. Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney Int. 2020;98:1135–1148. Available from: https://doi.org/10.1016/j.kint.2020.05.053
Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454–464. Available from: https://doi.org/10.1038/ki.2012.63
Ueda C, Horinouchi T, Inoki Y, Ichikawa Y, Tanaka Y, Kitakado H, et al. Clinical characteristics and outcomes of immune‑complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children. Pediatr Nephrol. 2024;39:2679–2689. Available from: https://doi.org/10.1007/s00467-024-06377-7
Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr Nephrol. 2017;32:43–57. Available from: https://doi.org/10.1007/s00467-015-3310-4
Licht C, Schlötzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. MPGN II – genetically determined by defective complement regulation? Pediatr Nephrol. 2007;22:2–9. Available from: https://doi.org/10.1007/s00467-006-0299-8
Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol. 2010;25:1409–1418. Available from: https://doi.org/10.1007/s00467-009-1322-7
Levin A. Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int. 1999;70:S41–S46. Available from: https://doi.org/10.1046/j.1523-1755.1999.07006.x
Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone—a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992;6:123–130. Available from: https://doi.org/10.1007/bf00866289
Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994;67:59–6. Available from: https://doi.org/10.1159/000187889
Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116:7926–7931. Available from: https://doi.org/10.1073/pnas.1820892116
Bomback AS, Kavanagh D, Vivarelli M, Meier M, Wang Y, Webb NJA, et al. Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy—study design of the APPEAR-C3G trial. Kidney Int Rep. 2022;7:2150–2159. Available from: https://doi.org/10.1016/j.ekir.2022.07.004
Schubart A, Flohr S, Junt T, Eder J. Low-molecular weight inhibitors of the alternative complement pathway. Immunol Rev. 2023;313:339–357. Available from: https://doi.org/10.1111/imr.13143
Patry C, Webb NJA, Feißt M, Krupka K, Becker J, Bald M, et al. Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network. Pediatr Nephrol. 2024;39:3569–3580. Available from: https://link.springer.com/article/10.1007/s00467-024-06476-5